Whereby certify that this correspondence is being deposited with the United States Postal strice as first class mail in an envelope addressed to:

Attorney Docket No.: 015542-00233

Luxton, David

COMPLIANT AMENDMENT UNDER 37

1653

RESPONSE TO NOTICE OF NON-

TECH CENTER 1600|2900

Assistant Commissioner for Patents

Washington, D.C. 20231

on 5/18/0

TOWNSEND and TOWNSEND and CREW LLP

By: and Kare

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Art Unit:

C.F.R. § 1.121

In re application of:

GREEN and BLASECKI

Application No.: 09/506,430

Filed: February 17, 2000

For: PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice of Non-Compliant Amendment Under 37 C.F.R. § 1.121, mailed April 19, 2001, Applicants provide a marked up version of the claims. Applicants believe, however, that this Notice was sent in error as the Amendment was a Preliminary Amendment and therefore did not fall under 37 C.F.R. § 1.121.

Please amend the above-identified application as follows:

IN THE CLAIMS:

A version of the claims with markings to show changes to the claims is provided in Appendix A. All of the pending claims are provided in Appendix B for the Examiner's convenience.

18. (Once Amended) A method of inhibiting neovascularization in a subject in need thereof comprising:

administering to said subject a pharmaceutical preparation comprising a pharmaceutically acceptable carrier and an amount of a compound effective to inhibit neovascularization with the formula of R'-Glu-Trp-R" or pharmaceutically acceptable salts

(W) (3)